ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. Show more

Location: 999 West Broadway, Vancouver, BC, V5Z 1K5, Canada | Website: https://www.essapharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

75.9M

52 Wk Range

$1.40 - $7.88

Previous Close

$1.75

Open

$1.75

Volume

72,074

Day Range

$1.71 - $1.75

Enterprise Value

-38.13M

Cash

113.9M

Avg Qtr Burn

-5.607M

Insider Ownership

6.02%

Institutional Own.

69.32%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Masofaniten (EPI-7386) (antiandrogen) + apalutamide and abiraterone acetate Details Cancer, Prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Masofaniten (EPI-7386) (antiandrogen) Monotherapy Details Castration-resistant prostate cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Masofaniten (EPI-7386) (antiandrogen) combo w/ enzalutamide Details Prostate cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.